Novel non-covalent ivermectin complex Didenectin is revolutionizing healthcare.
Description
In this article, we introduce a revolutionary breakthrough in coronavirus treatment, new ivermectin-based complex Didenectin (antiviral ivermectin), which is proved to reduce virus load to 100 times during 24h, leading to revolutionary rapid recovery of SARS-CoV-2 patients and Dengue patients within a record 24-hour timeframe.
The introduction of new non-covalent complex of ivermectin is changing the game in the healthcare industry. A novel non-covalent ivermectin-polymer complex Didenectin, already showed remarkable results on SARS-CoV-2 as well as on Dengue, a condition currently lacking any specific treatment. The complex should also be effective for the treatment of other viral infections that have shown in vitro sensitivity to ivermectin such as Chikungunya, Zika, Yellow fever, West Nile, avian influenza A (H7N7), HIV-1, Japanese encephalitis, tick-borne encephalitis, Epstein-Barr and others.
Ivermectin, a widely recognized anti-parasitic medication, exhibited remarkable efficacy in reducing viral load of SARS-CoV-2 by 93% and more within a single day under in vitro conditions, as demonstrated by Caly et al. However, translating these results to in vivo human studies was hindered by the substantial toxicity of ivermectin, preventing the achievement of the necessary IC50 2.4 μM and IC90 5 μM concentration of ivermectin in body tissues. The advent of the innovative Didenectin allowed to achieve a notable 3.4-fold reduction in oral toxicity and a remarkable 20-fold increase in solubility when compared to standard ivermectin. This led to the achievement of necessary IC50 2.4 μM and IC90 5 μM concentration of ivermectin and comparable reduction in viral load in vivo as previously demonstrated in vitro by Caly et al.
Didenectin's rapid and effective action demonstrates its potential not only for SARS-CoV-2 but potentially for Dengue as well. The first-ever cure of a Dengue patient within a 24-hour timeframe using Didenectin represents a monumental achievement in the field of antiviral research.
This article delves into the complex's mechanism of action, pre-clinical results, as well as a detailed description of the method for obtaining the ivermectin-polymer complex Didenectin, along with the complete formula and table of dosages.
Files
Didenectin.pdf
Files
(1.3 MB)
Name | Size | Download all |
---|---|---|
md5:3b68ae86d829c916f38fbece42d4f800
|
1.3 MB | Preview Download |